Janssen COVID-19 Vaccine Candidate Found Very Effective

The New England Journal of Medicine published an internal study on January 13, 2021, which found a single vaccine dose of Johnson & Johnson's Janssen COVID-19 vaccine candidate created an immune response that lasted at least 71 days. After a single vaccination, neutralizing antibodies against COVID-19 were observed in more than 90% of volunteers at Day 29 and 100% of the volunteers between the ages of 18 and 55 at Day 57.

'Our interim analysis indicates that vaccine candidate Ad26.COV2.S is safe and immunogenic in both younger and older adults.'

'This finding has supported our decision to proceed with phase 3 trials to evaluate the efficacy of either a single-dose or two-dose regimen of the lower dose (5×1010 viral particles) of Ad26.COV2.S.'